ALK and neoplasm: A study using next-generation sequencing (NGS) from 9 patients that had tumors that were ALK-negative by immunohistochemistry (IHC) revealed that 6 of them harbored ALK, ROS1, and platelet-derived growth factor receptor beta (PDGFRB) fusion proteins, suggesting that IMT is a largely oncogene-driven neoplasia [3].